PharmacyCodes



Valdecoxib [USAN] en es it fr

Categoria

Valdecoxib [USAN] Nombres de marca, Valdecoxib [USAN] Analogos

Valdecoxib [USAN] Marca los nombres de mezcla

  • No information avaliable

    • Valdecoxib [USAN] Formula quimica

    C16H14N2O3S

    Valdecoxib [USAN] RX enlace

    http://www.rxlist.com/cgi/generic/bextra.htm

    Valdecoxib [USAN] FDA hoja

    Valdecoxib_[USAN] FDA

    Valdecoxib [USAN] MSDS (hoja de seguridad de materiales)

    Valdecoxib [USAN] Sintesis de referencia

    No hay información disponible

    Valdecoxib [USAN] Peso molecular

    314.36 g/mol

    Valdecoxib [USAN] Punto de fusion

    No information avaliable

    Valdecoxib [USAN] H2O Solubilidad

    No hay información disponible

    Valdecoxib [USAN] Estado

    Solid

    Valdecoxib [USAN] LogP

    3.003

    Valdecoxib [USAN] Formas de dosificacion

    Tableta

    Valdecoxib [USAN] Indicacion

    Para el tratamiento de la artrosis y dismenorrea

    Valdecoxib [USAN] Farmacologia

    Valdecoxib, un ciclooxigenasa-2 (COX-2) inhibidores, se clasifica como antiinflamatorios no esteroideos (AINE). Valdecoxib se utiliza para sus actividades anti-inflamatorias, analgésicas y antipiréticas en el manejo de la osteoartritis (OA) y para el tratamiento de la dismenorrea o dolor agudo. A diferencia de celecoxib, valdecoxib carece de una cadena sulfonamida y no requiere de enzimas del citocromo P450 para el metabolismo.

    Valdecoxib [USAN] Absorcion

    No hay información disponible

    Valdecoxib [USAN] Toxicidad

    No hay información disponible

    Valdecoxib [USAN] Informacion de Pacientes

    BEXTRA can cause GI discomfort and, rarely, more serious GI side effects, which may result in hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up Effects ó Risk of GI Ulceration, Bleeding, and Perforation).

    Patients should report to their physicians, signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, weight gain, or edema.

    Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and flu-like symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical attention.

    Patients should also be instructed to seek immediate emergency help in the case of an anaphylactoid reaction.

    In late pregnancy, BEXTRA should be avoided because it may cause premature closure of the ductus arteriosus.

    Valdecoxib [USAN] Organismos afectados

    Humanos y otros mamíferos